Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $17.61 Analyst target: $23.33 Upside: 32.48%
Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.